Head-to-head · WeighScore
Eve vs Ilant Health
The verdict
Eve takes it — 66.3/100 to 56.8/100.
Eve grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eve is a women's-health-focused GLP-1 telehealth platform — distinctive positioning in a largely gender-neutral market — offering both compounded semaglutide and tirzepatide (including an oral sublingual…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Eve | Ilant Health |
|---|---|---|
| WeighScore | 66.3/100 | 56.8/100 |
| Grade | C | C |
| Scorecard rank | #189 | #407 |
| Semaglutide | $195/mo (compounded) | Not disclosed |
| Tirzepatide | $195/mo (compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #189 · C
Strengths
- Genuinely women's-health-focused — fills a real gap among gender-neutral GLP-1 competitors
- Both compounded and brand-name FDA-approved options (Wegovy/Ozempic/Mounjaro) on one platform — rare
- LegitScript Certified with a verifiable ID
- Publishes the FDA compounded-medication disclaimer
- Oral sublingual semaglutide offered alongside injectable
Where it loses points
- Full states-served list not disclosed publicly
- 503A pharmacy partner not named, and 503A vs 503B status not specified
- Named medical director / clinical leadership not disclosed
- Corporate legal entity not disclosed
- Governing law / arbitration venue not stated
Graded #407 · C
Strengths
- Value-based, outcomes-driven obesity care model
- Includes GLP-1 medications with transparent drug pricing for sponsors
- Care team of board-certified obesity providers and behavioral specialists
- Dietitians and peer navigators support adherence
- Data-driven stratification targets the right interventions
Where it loses points
- Distributed via employers and health plans, not direct cash-pay
- Individuals generally cannot enroll without sponsor coverage
- No public consumer pricing for GLP-1
- Access gated behind organizational buyers
- Not suited to consumers wanting direct-to-door GLP-1
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.